Biogen (BIIB)
NASDAQ:BIIB
Want to see BIIB full AI Analyst Report?
Total Valuation
Biogen has a market cap or net worth of $28.49B. The enterprise value is $31.67B.
Market Cap$28.49B
Enterprise Value$31.67B
Share Statistics
Biogen has 147,637,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding147,637,120
Owned by Insiders0.19%
Owned by Institutions21.43%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 6.62%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)6.62%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.29M
Profits Per Employee170.01K
Employee Count7,605
Asset Turnover0.33
Inventory Turnover1.34
Valuation Ratios
The current PE Ratio of Biogen is 21.1. Biogen’s PEG ratio is -0.95.
PE Ratio21.1
PS Ratio2.63
PB Ratio1.41
Price to Fair Value1.41
Price to FCF12.59
Price to Operating Cash Flow10.96
PEG Ratio-0.95
Income Statement
In the last 12 months, Biogen had revenue of 9.81B and earned 1.29B in profits. Earnings per share was 8.85.
Revenue9.81B
Gross Profit6.91B
Operating Income1.88B
Pretax Income1.40B
Net Income1.29B
EBITDA3.10B
Earnings Per Share (EPS)8.85
Cash Flow
In the last 12 months, operating cash flow was 2.59B and capital expenditures 32.30M, giving a free cash flow of 2.62B billion.
Operating Cash Flow2.59B
Free Cash Flow2.62B
Free Cash Flow per Share17.77
Dividends & Yields
Biogen pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change49.07%
50-Day Moving Average186.07
200-Day Moving Average161.73
Relative Strength Index (RSI)45.75
Average Volume (3m)1.14M
Important Dates
Biogen upcoming earnings date is Jul 29, 2026, Before Open (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateJul 29, 2026
Ex-Dividend Date―
Financial Position
Biogen as a current ratio of 2.68, with Debt / Equity ratio of 35.18%
Current Ratio2.68
Quick Ratio2.03
Debt to Market Cap0.26
Net Debt to EBITDA1.27
Interest Coverage Ratio7.63
Taxes
In the past 12 months, Biogen has paid 108.11M in taxes.
Income Tax108.11M
Effective Tax Rate0.08
Enterprise Valuation
Biogen EV to EBITDA ratio is 9.60, with an EV/FCF ratio of 14.51.
EV to Sales3.03
EV to EBITDA9.60
EV to Free Cash Flow14.51
EV to Operating Cash Flow13.50
Balance Sheet
Biogen has $4.28B in cash and marketable securities with $6.56B in debt, giving a net cash position of -$2.28B billion.
Cash & Marketable Securities$4.28B
Total Debt$6.56B
Net Cash-$2.28B
Net Cash Per Share-$15.44
Tangible Book Value Per Share$17.64
Margins
Gross margin is 69.77%, with operating margin of 19.14%, and net profit margin of 13.18%.
Gross Margin69.77%
Operating Margin19.14%
Pretax Margin14.29%
Net Profit Margin13.18%
EBITDA Margin31.60%
EBIT Margin22.07%
Analyst Forecast
The average price target for Biogen is $218.76, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$218.76
Price Target Upside23.35% Upside
Analyst ConsensusModerate Buy
Analyst Count26
Revenue Growth Forecast2.11%
EPS Growth Forecast-7.88%